Rupatadine is a Small Molecule owned by J Uriach Y Compania, and is involved in 18 clinical trials, of which 16 were completed, and 2 are ongoing.
Rupatadine acts as a long-acting, non-sedative antagonist at histaminergic H1-receptors and also antagonizes the platelet-activating factor (PAF). Both histamine and PAF causes bronchoconstriction and lead to an increase in the vascular permeability, acting as a mediator in the inflammatory process, which is responsible for the bronchial hyperreactivity. Rupatadine has other anti-allergic properties also, such as inhibition of mastocytes, degranulation, induced by the immunological and non-immunological stimulants and the inhibition of release of cytokines, particularly the tumor necrosis factor alpha (TNF-alpha) in human mastocytes and monocytes.
The revenue for Rupatadine is expected to reach a total of $218m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rupatadine NPV Report.
Rupatadine fumarate (Rupafin/Wystamm/Rescetina/Rupall) is a second generation, non-sedating, long-acting anti-histamine drug act as anti-allergic agent. It is formulated in the form of solution and tablets for oral route of administration. Rupatadine is indicated for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) in children 2 to 11 years and urticaria in children 2 to 11 years and symptomatic treatment of seasonal or perennial allergic rhinitis.
Medexus Pharmaceuticals Overview
Medexus Pharmaceuticals (MDI) is a pharmaceutical company with a focus on the therapeutic areas of rheumatology, specialty oncology, auto-immune disease, allergy, and pediatric diseases. It provides prescription and over the counter brands to patients and healthcare professionals. It operates in North American. MDI is headquartered in Bolton, Ontario, Canada.
The company reported revenues of (US Dollars) US$76.7 million for the fiscal year ended March 2022 (FY2022), a decrease of 3.7% over FY2021. The operating loss of the company was US$15 million in FY2022, compared to an operating loss of US$1.4 million in FY2021. The net loss of the company was US$2.9 million in FY2022, compared to a net loss of US$28.3 million in FY2021.
Quick View – Rupatadine
|Highest Development Stage|